Y-mAbs Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
YMAB Nasdaq 8731 https://www.ymabs.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Y-mAbs Therapeutics Inc

Y-mAbs Therapeutics (NASDAQ:YMAB investor three-year losses grow to 81% as the stock sheds US$53m this past week - Jun 2nd, 2023 7:15 pm
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO - May 26th, 2023 1:00 pm
Y-mAbs Announces Presentation of Naxitamab Data at ASCO - May 26th, 2023 1:00 pm
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil - May 23rd, 2023 1:00 pm
New Forecasts: Here's What Analysts Think The Future Holds For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - May 13th, 2023 12:18 pm
Y-mAbs Therapeutics First Quarter 2023 Earnings: Beats Expectations - May 10th, 2023 10:14 am
Q1 2023 Y-mAbs Therapeutics Inc Earnings Call - May 10th, 2023 6:52 am
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates - May 8th, 2023 9:15 pm
Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance - May 8th, 2023 8:01 pm
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know - May 1st, 2023 2:01 pm
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023 - Apr 28th, 2023 1:00 pm
Y-mAbs Announces Presentation of Naxitamab data at AACR - Apr 18th, 2023 1:00 pm
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Surges 104% Yet Its Low P/S Is No Reason For Excitement - Apr 17th, 2023 2:57 pm
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2022 Earnings Call Transcript - Apr 5th, 2023 11:44 pm
Wall Street Analysts Believe Y-mAbs Therapeutics, Inc. (YMAB) Could Rally 111.13%: Here's is How to Trade - Apr 5th, 2023 1:55 pm
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA - Apr 5th, 2023 1:00 pm
Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains? - Apr 4th, 2023 9:12 am
Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates - Mar 30th, 2023 9:25 pm
Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments - Mar 30th, 2023 8:01 pm
Dow futures down 0.1%, Virgin Orbit tanks 41.2% after-hours - Mar 30th, 2023 6:42 pm